Ionis Pharmaceuticals News and Activities
Presence
Ionis Pharmaceuticals develops RNA-targeted medicines and related drug discovery services. Its products and services support patients, healthcare providers, and pharmaceutical partners in treating serious diseases.
Ionis Pharmaceuticals products and services overview:
- RNA medicines
- Drug discovery
- Licensing agreements
- Clinical development
- Rare disease therapies
Revenue: ~$700 million
Employees: 1,100
Headquarters: Carlsbad, United States (USA)
Ionis Pharmaceuticals is one of the...
Ionis Pharmaceuticals is a company listed under the stock ticker IONS (US).
Executives
View the org chart displaying its 23 main executives
Most searched biographies at Ionis Pharmaceuticals
- Brett Monia, Chief Executive Officer and Director
- Peter Reikes, Director
- Joseph Loscalzo, Chairman of The Board
Popular executive movements at Ionis Pharmaceuticals
- Ludwig Hantson has joined the company as Director (posted on June 9 2026).
- Joseph Wender, Director, will retire on Jun. 4, 2026 (posted on March 9 2026).
- Peter Reikes will join the company as Director on Jun. 4, 2026 (posted on March 9 2026).
Click here to view some more movements at Ionis Pharmaceuticals
Create your alert
to follow the executive moves at Ionis Pharmaceuticals.
Biotechnology
Ionis Pharmaceuticals has 2,413 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Vertex Pharmaceuticals (United States (USA)).
Popular M&A news in Biotechnology
- Ollin Biosciences has just announced a $330 Million fundraising (posted on June 24 2026).
- RQ Biotechnology has just announced a $86 Million fundraising (posted on June 24 2026).
- Boundless Bio has filed its IPO. Its stock ticker will be AATD. (posted on June 23 2026).
Popular contacts in Biotechnology
News
Press releases by Ionis Pharmaceuticals
- Ionis reports third quarter 2023 financial results | Ionis Pharmaceuticals, Inc.
- Ionis to present at upcoming investor conferences | Ionis Pharmaceuticals, Inc.
- Ionis to present at upcoming investor conferences | Ionis Pharmaceuticals, Inc.
- Ionis reports second quarter 2023 financial results | Ionis Pharmaceuticals, Inc.
- Ionis completes enrollment in landmark Phase 3 CARDIO-TTRansform study in patients with TTR-mediated amyloid cardiomyopathy | Ionis Pharmaceuticals, Inc.
- Ionis enters collaboration to advance next generation program targeting Lp(a) for cardiovascular disease | Ionis Pharmaceuticals, Inc.
- Ionis to hold second quarter 2023 financial results webcast | Ionis Pharmaceuticals, Inc.
- Ionis expands eplontersen agreement with AstraZeneca to include exclusive rights in Latin America | Ionis Pharmaceuticals, Inc.
- Eplontersen continued to show improvement in ATTRv-PN through 85 weeks | Ionis Pharmaceuticals, Inc.
- Ionis to present at upcoming investor conference | Ionis Pharmaceuticals, Inc.
- View more press releases Close
Social media about Ionis Pharmaceuticals
- Ionis Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
- Ionis Pharmaceuticals on LinkedIn, X (Twitter) & YouTube
